{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:26:13Z","timestamp":1794536773626,"version":"4.9.1"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Postoperative radiotherapy (mainly fractionated intensity-modulated radiotherapy) is indicated after surgery for early-stage oral cavity squamous cell carcinoma (OCSCC) and oropharyngeal squamous cell carcinoma (OPSCC) in the presence of high-risk margins. Postoperative brachytherapy is a treatment option, but it is not always feasible; stereotactic body radiotherapy (SBRT) may offer a noninvasive alternative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate late toxic effects and 2-year local control after postoperative SBRT to the primary tumor bed in patients with early-stage OCSCC or OPSCC and high-risk resection margins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This national, multicenter, single-arm, phase 2 nonrandomized clinical trial was conducted across 18 academic centers in France in the Groupe d\u2019Oncologie Radioth\u00e9rapie T\u00eate et Cou (GORTEC) network. Adults with pT1 to pT2 OCSCC or OPSCC and R1 or smaller than 5 mm margins, pN0 or pN1 without extracapsular extension, no indication for neck irradiation, and not planned for adjuvant chemotherapy were enrolled between April 2018 and August 2021. Final analysis was conducted from February to May 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>SBRT to the surgical bed, 36 Gy in 6 fractions over 2 weeks, using volumetric modulated arctherapy (VMAT) or CyberKnife, with image guidance and quality assurance protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was the 2-year rate of grade 3 or greater late toxic effects (&amp;amp;gt;90 days after treatment), per Common Terminology Criteria for Adverse Events version 4.03. The key secondary end point was 2-year local control. Quality of life (QoL) was assessed using European Organization for Research and Treatment of Cancer (EORTC) core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire Head and Neck Module (QLQ-HN35).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 90 patients (median [range] age, 64 [31-87] years; 51 [56.5%] male), at 2 years, 2 patients (2.2%) had grade 3 late toxic effects, while 13 patients (14.6%) experienced at least 1 grade 3 late toxic effect during the 2-year follow-up period, mainly soft-tissue necrosis and osteoradionecrosis, most of which were transitory. The 2-year local control rate was 92.0% (95% CI, 84.6%-96.4%). Acute grade 3 or greater toxic effects were limited to mucositis (28.9%; 95% CI, 19.8%-39.4%), mostly resolving by 3 months. Median follow-up was 25 months (range, 3-31 months). Disease-free and overall survival at 2 years were 73.3% (95% CI, 63.4%-81.7%) and 88.8% (95% CI, 80.9%-94.2%), respectively. QoL scores showed a transient decline at 1 month followed by recovery and improvement at 12 and 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this phase 2 nonrandomized clinical trial, postoperative primary tumor bed SBRT for early-stage OCSCC and OPSCC with high-risk margins was associated with manageable toxic effects and high rates of local control. These findings support SBRT as a promising approach in carefully selected patients, but confirmatory randomized trials are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03401840\">NCT03401840<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.49975","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:33Z","timestamp":1766073633000},"page":"e2549975","source":"Crossref","is-referenced-by-count":6,"title":["Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers"],"prefix":"10.1001","volume":"8","author":[{"given":"Julian","family":"Biau","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France"},{"name":"INSERM U1240 IMoST, Universit\u00e9 Clermont Auvergne, Clermont-Ferrand, France"},{"name":"UMR 501, Centre d\u2019Investigation Clinique, Clermont-Ferrand, F-63001 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xushan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, H\u00f4pital Nord Franche-Comt\u00e9 and CHRU Besan\u00e7on, Montb\u00e9liard and Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Liem","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Oscar Lambret, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Faivre","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut de Canc\u00e9rologie de Lorraine, Vandoeuvre les Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elife","family":"Eker","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Dor\u00e9","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut de Canc\u00e9rologie de l\u2019Ouest, Saint Herblain, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Maingon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Groupe Hospitalier La Piti\u00e9 Salp\u00e9tri\u00e8re (AP-HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Vulquin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Georges Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Alfonsi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Sainte Catherine, Avignon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Thureau","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, H\u00f4pital Tenon AP-HP, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Racadot","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Thivat","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France"},{"name":"INSERM U1240 IMoST, Universit\u00e9 Clermont Auvergne, Clermont-Ferrand, France"},{"name":"UMR 501, Centre d\u2019Investigation Clinique, Clermont-Ferrand, F-63001 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Molnar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France"},{"name":"INSERM U1240 IMoST, Universit\u00e9 Clermont Auvergne, Clermont-Ferrand, France"},{"name":"UMR 501, Centre d\u2019Investigation Clinique, Clermont-Ferrand, F-63001 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Boisselier","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut du Cancer de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Guihard","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, ICANS, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Gallocher","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinique Pasteur, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dupin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, CHU de Bordeaux, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Batard","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bourhis","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, CHUV, Lausanne, Suisse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Lapeyre","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"4-5","key":"zoi251341r1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.oraloncology.2008.06.002","article-title":"Global epidemiology of oral and oropharyngeal cancer.","volume":"45","author":"Warnakulasuriya","year":"2009","journal-title":"Oral Oncol"},{"issue":"1","key":"zoi251341r2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1288\/00005537-199501000-00013","article-title":"Transoral laser resection with staged discontinuous neck dissection for oral cavity and oropharynx squamous cell carcinoma.","volume":"105","author":"Eckel","year":"1995","journal-title":"Laryngoscope"},{"issue":"11","key":"zoi251341r3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/hed.20269","article-title":"Surgical margin determination in head and neck oncology: current clinical practice: the results of an International American Head and Neck Society Member Survey.","volume":"27","author":"Meier","year":"2005","journal-title":"Head Neck"},{"issue":"2","key":"zoi251341r4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/MOO.0b013e328058670f","article-title":"Status of primary tumour surgical margins in squamous head and neck cancer: prognostic implications.","volume":"15","author":"Bradley","year":"2007","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"4","key":"zoi251341r5","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.ijrobp.2008.05.024","article-title":"Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.","volume":"73","author":"Gomez","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"zoi251341r6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/hed.20091","article-title":"Postoperative irradiation for squamous cell carcinoma of the oral cavity: 35-year experience.","volume":"26","author":"Hinerman","year":"2004","journal-title":"Head Neck"},{"issue":"1","key":"zoi251341r7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0360-3016(93)90139-M","article-title":"Postoperative radiation therapy for squamous cell carcinomas of the oral cavity and oropharynx: impact of therapy on patients with positive surgical margins.","volume":"25","author":"Zelefsky","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi251341r8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0360-3016(97)00717-7","article-title":"Close or positive margins after surgical resection for the head and neck cancer patient: the addition of brachytherapy improves local control.","volume":"40","author":"Beitler","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi251341r9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.canrad.2013.01.007","article-title":"Brachytherapy for head and neck cancers.","volume":"17","author":"Lapeyre","year":"2013","journal-title":"Cancer Radiother"},{"issue":"2","key":"zoi251341r10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.radonc.2009.01.005","article-title":"GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas.","volume":"91","author":"Mazeron","year":"2009","journal-title":"Radiother Oncol"},{"issue":"11","key":"zoi251341r11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s00066-004-9196-x","article-title":"Treatment of oral cavity and oropharyngeal cancer. indications, technical aspects, and results of interstitial brachytherapy.","volume":"180","author":"Strnad","year":"2004","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"zoi251341r12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.brachy.2014.09.011","article-title":"Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue.","volume":"14","author":"Goineau","year":"2015","journal-title":"Brachytherapy"},{"issue":"2","key":"zoi251341r13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.radonc.2016.10.008","article-title":"GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update\u2014improvement by cross sectional imaging based treatment planning and stepping source technology.","volume":"122","author":"Kov\u00e1cs","year":"2017","journal-title":"Radiother Oncol"},{"issue":"1","key":"zoi251341r14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12885-020-07231-3","article-title":"A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.","volume":"20","author":"Biau","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"zoi251341r15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.ijrobp.2008.12.075","article-title":"Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.","volume":"75","author":"Heron","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"zoi251341r16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/lary.24441","article-title":"Adjuvant stereotactic body radiotherapy\u00b1cetuximab following salvage surgery in previously irradiated head and neck cancer.","volume":"124","author":"Vargo","year":"2014","journal-title":"Laryngoscope"},{"issue":"3","key":"zoi251341r17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ijrobp.2014.11.023","article-title":"A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.","volume":"91","author":"Vargo","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"zoi251341r18","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.ijrobp.2011.05.019","article-title":"Stereotactic body radiotherapy: a promising treatment option for the boost of oropharyngeal cancers not suitable for brachytherapy: a single-institutional experience.","volume":"82","author":"Al-Mamgani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"zoi251341r19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.oraloncology.2013.07.007","article-title":"Brachytherapy or stereotactic body radiotherapy boost for early-stage oropharyngeal cancer: comparable outcomes of two different approaches.","volume":"49","author":"Al-Mamgani","year":"2013","journal-title":"Oral Oncol"},{"issue":"2","key":"zoi251341r20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2013.08.012","article-title":"Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.","volume":"109","author":"Lartigau","year":"2013","journal-title":"Radiother Oncol"},{"issue":"3","key":"zoi251341r21","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.ijrobp.2016.02.049","article-title":"Risk of severe toxicity according to site of recurrence in patients treated with stereotactic body radiation therapy for recurrent head and neck cancer.","volume":"95","author":"Ling","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi251341r22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijrobp.2018.01.044","article-title":"Head and neck tumor control probability: radiation dose-volume effects in stereotactic body radiation therapy for locally recurrent previously-irradiated head and neck cancer: report of the AAPM Working Group.","volume":"110","author":"Vargo","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi251341r23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.radonc.2015.07.041","article-title":"CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines.","volume":"117","author":"Brouwer","year":"2015","journal-title":"Radiother Oncol"},{"issue":"6","key":"zoi251341r24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.brachy.2013.07.002","article-title":"Interstitial pulsed-dose-rate brachytherapy for head and neck cancer\u2014single-institution long-term results of 385 patients.","volume":"12","author":"Strnad","year":"2013","journal-title":"Brachytherapy"},{"key":"zoi251341r25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ctro.2017.12.002","article-title":"Surgery vs. primary radiotherapy in early-stage oropharyngeal cancer.","volume":"9","author":"Pedro","year":"2017","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"zoi251341r26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.oooo.2024.04.008","article-title":"The incidence of osteoradionecrosis of the jaws in oral cavity cancer patients treated with intensity-modulated radiotherapy: a systematic review and meta-analysis.","volume":"138","author":"de Almeida-Silva","year":"2024","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"1","key":"zoi251341r27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0360-3016(00)00538-1","article-title":"Postoperative brachytherapy alone for T1-2 N0 squamous cell carcinomas of the oral tongue and floor of mouth with close or positive margins.","volume":"48","author":"Lapeyre","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi251341r28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00066-021-01870-6","article-title":"Adjuvant brachytherapy for oral squamous cell carcinomas: a single-center experience comparing low-dose and pulsed-dose-rate techniques.","volume":"198","author":"Mattei","year":"2022","journal-title":"Strahlenther Onkol"},{"issue":"34","key":"zoi251341r29","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1200\/JCO.20.01661","article-title":"Equivalence Randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer.","volume":"38","author":"Garrel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi251341r30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1056\/NEJMoa1506007","article-title":"Elective versus therapeutic neck dissection in node-negative oral cancer.","volume":"373","author":"D\u2019Cruz","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi251341r31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores.","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi251341r32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi251341r33","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1200\/JCO.2007.14.6647","article-title":"Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.","volume":"26","author":"Langendijk","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi251341r34","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1200\/JCO.1999.17.3.1008","article-title":"Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35.","volume":"17","author":"Bjordal","year":"1999","journal-title":"J Clin Oncol"},{"key":"zoi251341r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.04.005","author":"So","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842891\/biau_2025_oi_251341_1765387226.12439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:33Z","timestamp":1766073633000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842891"}},"subtitle":["The STEREOPOSTOP\u2013GORTEC 2017-03 Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.49975","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}